

Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

<https://marketpublishers.com/r/GE987C530F8EEN.html>

Date: July 2017

Pages: 358

Price: US\$ 4,599.00 (Single User License)

ID: GE987C530F8EEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

The pharmaceutical Industry is a multibillion market consisting of innovator drugs & generics. The pharmaceutical market consists of a companies involved in the research, development, manufacturing and commercialization of drugs for human & animal use. Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. Biologics are defined as pharmaceutical products obtained from living cells or micro-organisms. These are complex & large molecules consisting of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of these.

The biologics drug discovery involves target identification, hit-to-lead stage, lead identification & optimization. Technologies used for the development of biologics include genomics, proteomics, microarrays, cell cultures, phage display technologies and monoclonal antibody technologies among others. The market analysis includes an in-depth examination of the key ecosystem players and key strategies & developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities and challenges) and industry analysis.

The purpose of the study is to gain a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological

advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the biologics drug discovery market. The market has been segmented into 'product', 'method', 'manufacture' and 'geographical regions'. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

What are the major market drivers, challenges and opportunities in the global biologics drug discovery market and their case studies?

How the biologics drug discovery market evolve and what did is its scope in the future?

What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2016 and 2025?

How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025?

What are the influencing factors that may affect the market share of the key players?

How will the industry evolve during the forecast period between 2016 and 2025?

What are the key developmental strategies implemented by the key players to stand out in this market?

What will be the growth rate of the outsourced manufacturing segment during the forecast period?

Who are the key outsourced manufacturers of the biologics drug discovery market market?

How the market has been segmented on the basis of phase/method? Which method is highly adopted in the biologics drug discovery process?

Which technologies have been covered in the Target Identification phase?

What will be the value of oncology biologics drug discovery segment by 2025?

Which geographical location will contribute to the highest sales of biologics?

In Europe, which country is dominating the biologics drug discovery market? Also, which country will show the highest growth rate?

The key players which have significant contributions to the biologics drug discovery market are Albany Molecular Research Inc., GenScript, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Lilly, Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG, and Biocon Ltd. among others.

Contents

EXECUTIVE SUMMARY

1 REPORT SCOPE

- 1.1 Scope of the Report
- 1.2 Global Biologics Drug Discovery Market Segmentation
- 1.3 Key Learnings
- 1.4 Research Methodology
 - 1.4.1. Data Triangulation
 - 1.4.2. Key Data Points From Secondary Sources
 - 1.4.3. Key Data Points From Primary Sources
 - 1.4.4. Top-Down Approach (Segmental Analysis)
 - 1.4.5. Bottom-Up Approach (Segmental Analysis)
 - 1.4.6. Assumptions and Limitations
 - 1.4.7. Data and Prediction Modelling

2 MARKET OVERVIEW

- 2.1 Introduction
- 2.2 Market Dynamics
 - 2.2.1. Market Drivers
 - 2.2.2. Market Challenges
 - 2.2.3. Market Opportunities

3 INDUSTRY INSIGHTS

- 3.1. Regulatory Scenario
- 3.2. Patent Landscape

4 COMPETITIVE LANDSCAPE

- 4.1 Share of Key Developments & Strategies
 - 4.1.1. Collaboration/ Partnership/ Joint Venture/ Licensing Agreement
 - 4.1.2. Mergers & Acquisitions
 - 4.1.3. Business Expansion
 - 4.1.4. Products/Platform/Services Launch
 - 4.1.5. Others

4.2. Porter's Five Forces Analysis

- 4.2.1. Bargaining Power of Suppliers
- 4.2.2. Bargaining Power of Buyers
- 4.2.3. Threat of New Entrants>
- 4.2.4. Threat of Substitutes
- 4.2.5. Intensity of Competitive Rivalry

5 GLOBAL BIOLOGICS DRUG DISCOVERY MARKET, BY PRODUCT

5.1. Small Molecule Vs. Biologicals

5.2. Biologicals

- 5.2.1. Monoclonal Antibodies
- 5.2.2. Recombinant Proteins
- 5.2.3. Other biologics

6 GLOBAL BIOLOGICS DRUG DISCOVERY MARKET, BY PHASE

6.1. Target Identification/Validation

- 6.1.1. Functional Genomics/Proteomics
- 6.1.2. Computational Approach/In-silico
- 6.1.3. Cell based Assay
- 6.1.4. Knock out studies/CRISPR/Cas9
- 6.1.5. Animal/Disease Based Models

6.2. Hit Generation

6.3. Lead Identification

6.4. Lead Optimization

7 GLOBAL BIOLOGICS DRUG DISCOVERY MARKET, BY MANUFACTURE TYPE

7.1. Type of Manufacturing

- 7.1.1. In-House Manufacturing
- 7.1.2. Advantages of Outsourcing Development
- 7.1.3. Outsourced Manufacturing

8 GLOBAL BIOLOGICS DRUG DISCOVERY MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.3. Europe

8.4. Asia-Pacific

8.5 Rest Of the World

9 COMPANY PROFILES

9.1. Abbvie Inc.

9.1.1. Overview

9.1.2. Product Portfolio

9.1.3. Financials

9.1.3.1 Financial Summary

9.1.4. Abbvie Inc.: SWOT Analysis

9.2. Albany Molecular Research Inc.

9.2.1. Overview

9.2.2. Product/Services Portfolio

9.2.3. Financials

9.2.3.1 Financial Summary

9.2.4. Albany Molecular Research Inc.: SWOT Analysis

9.3. Allergan plc.

9.3.1. Overview

9.3.2. Product Portfolio

9.3.3. Financials

9.3.3.1 Financial Summary

9.3.4. Allergan plc.: SWOT Analysis

9.4. Amgen Inc.

9.4.1. Overview

9.4.2. Product Portfolio

9.4.3. Financials

9.4.3.1 Financial Summary

9.4.4. Amgen Inc.: SWOT Analysis

9.5. Aptuit

9.5.1. Overview

9.5.2. Product/Services Portfolio

9.5.3. Financials

9.5.3.1 Financial Summary

9.5.4. Amgen Inc.: SWOT Analysis

9.6. Atellas Pharma Inc.

9.6.1. Overview

9.6.2. Product Portfolio

9.6.3. Financials

- 9.6.3.1. Financial Summary
- 9.6.4. Astellas Pharma Inc.: SWOT Analysis
- 9.7. AstraZeneca PLC
 - 9.7.1. Overview
 - 9.7.2. Product Portfolio
 - 9.7.3. Financials
 - 9.7.3.1. Financial Summary
 - 9.7.4. AstraZeneca Plc: SWOT Analysis
- 9.8. Bayer AG
 - 9.8.1. Overview
 - 9.8.2. Product Portfolio
 - 9.8.3. Financials
 - 9.8.3.1. Financial Summary
 - 9.8.4. Bayer AG: SWOT Analysis
- 9.9. Biocon Ltd.
 - 9.9.1. Overview
 - 9.9.2. Product Portfolio
 - 9.9.3. Financials
 - 9.9.3.1. Financial Summary
 - 9.9.4. Bayer AG: SWOT Analysis
- 9.10. Boehringer Ingelheim GmbH
 - 9.10.1. Overview
 - 9.10.2. Product Portfolio
 - 9.10.3. Financials
 - 9.10.3.1. Financial Summary
 - 9.10.4. Boehringer Ingelheim GmbH: SWOT Analysis
- 9.11. BRISTOL-MYERS SQUIBB COMPANY
 - 9.11.1. Overview
 - 9.11.2. Product Portfolio
 - 9.11.3. Financials
 - 9.11.3.1. Financial Summary
 - 9.11.4. BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
- 9.12. Charles River Laboratories International, Inc.
 - 9.12.1. Overview
 - 9.12.2. Product/Services Portfolio
 - 9.12.3. Financials
 - 9.12.3.1. Financial Summary
 - 9.12.4. Charles River Laboratories International Inc: SWOT Analysis
- 9.13. Eli Lilly and Company

- 9.13.1. Overview
- 9.13.2. Products Portfolio
- 9.13.3. Financials
 - 9.13.3.1. Financial Summary
- 9.13.4. Eli Lilly and Company: SWOT Analysis
- 9.14. Evotec AG
 - 9.14.1. Overview
 - 9.14.2. Product/Services Portfolio
 - 9.14.3. Financials
 - 9.14.3.1. Financial Summary
 - 9.14.4. Evotec AG: SWOT Analysis
- 9.15. F. Hoffmann-La Roche AG
 - 9.15.1. Overview
 - 9.15.2. Product Portfolio
 - 9.15.3. Financials
 - 9.15.3.1. Financial Summary
 - 9.15.4. F. Hoffmann-La Roche AG: SWOT Analysis
- 9.16. GenScript
 - 9.16.1. Overview
 - 9.16.2. Product/Services Portfolio
 - 9.16.3. Corporate Summary
 - 9.16.4. GenScript: SWOT Analysis
- 9.17. Gilead Sciences Inc.
 - 9.17.1. Overview
 - 9.17.2. Product Portfolio
 - 9.17.3. Financials
 - 9.17.3.1. Financial Summary
 - 9.17.4. Gilead Sciences Inc.: SWOT Analysis
- 9.18. GlaxoSmithKline Plc
 - 9.18.1. Overview
 - 9.18.2. Product Portfolio
 - 9.18.3. Financials
 - 9.18.3.1. Financial Summary
 - 9.18.4. GlaxoSmithKline Plc: SWOT Analysis
- 9.19. JOHNSON & JOHNSON
 - 9.19.1. Overview
 - 9.19.2. Product Portfolio
 - 9.19.3. Financials
 - 9.19.3.1. Financial Summary

- 9.19.4. JOHNSON & JOHNSON: SWOT Analysis
- 9.20. Laboratory Corporation of America Holdings
 - 9.20.1. Overview
 - 9.20.2. Product/Services Portfolio
 - 9.20.3. Financials
 - 9.20.3.1. Financial Summary
 - 9.20.4. Laboratory Corporation of America Holdings: SWOT Analysis
- 9.21. Merck KGaA
 - 9.21.1. Overview
 - 9.21.2. Product Portfolio
 - 9.21.3. Financials
 - 9.21.3.1. Financial Summary
 - 9.21.4. Merck KGaA: SWOT Analysis
- 9.22. Merck & CO., Inc.
 - 9.22.1. Overview
 - 9.22.2. Product Portfolio
 - 9.22.3. Financials
 - 9.22.3.1. Financial Summary
 - 9.22.4. Merck & CO., Inc.: SWOT Analysis
- 9.23. Novartis AG
 - 9.23.1. Overview
 - 9.23.2. Product Portfolio
 - 9.23.3. Financials
 - 9.23.3.1. Financial Summary
 - 9.23.4. Novartis AG: SWOT Analysis
- 9.24. NOVO NORDISK
 - 9.24.1. Overview
 - 9.24.2. Product Portfolio
 - 9.24.3. Financials
 - 9.24.3.1. Financial Summary
 - 9.24.4. NOVO NORDISK: SWOT Analysis
- 9.25. Pfizer Inc.
 - 9.25.1. Overview
 - 9.25.2. Product Portfolio
 - 9.25.3. Financials
 - 9.25.3.1. Financial Summary
 - 9.25.4. Pfizer Inc.: SWOT Analysis
- 9.26. Sanofi
 - 9.26.1. Overview

- 9.26.2. Product Portfolio
- 9.26.3. Financials
 - 9.26.3.1. Financial Summary
- 9.26.4. Sanofi: SWOT Analysis
- 9.27. Teva Pharmaceuticals
 - 9.27.1. Overview
 - 9.27.2. Product Portfolio
 - 9.27.3. Financials
 - 9.27.3.1. Financial Summary
 - 9.27.4. Teva Pharmaceuticals: SWOT Analysis
- 9.28. WuXi Apptec
 - 9.28.1. Overview
 - 9.28.2. Product/Services Portfolio
 - 9.28.3. Corporate Summary
 - 9.28.4. WuXi Apptec: SWOT Analysis

List Of Tables

LIST OF TABLES

- 1 Global Biologics Drug Discovery Market (2016 & 2023)
- 2 Drug Approvals by FDA
- 3 Percentage of total regional population aged 65 years & above: 2015 & 2030
- 4 Regulatory Scenario across the world
- 5 Patent Landscape
- 6 Partnership/Collaboration/Joint Ventures/Licensing Agreements
- 7 Mergers & Acquisitions
- 8 Business Expansion
- 9 Products/Platform/Services Launch
- 10 Other-Funding, Milestones, Awards
- 11 Factors Affecting Bargaining Power of Suppliers
- 12 Factors Affecting the Bargaining Power of Buyers
- 13 Factors Affecting Threat of New Entrant
- 14 Factors Affecting the Threat of Substitutes
- 15 Factors Affecting the Intensity of Competitive Rivalry
- 16 Difference between Small Molecule and Biologics
- 17 Examples of marketed biological products.
- 18 Some of the marketed products with cells used
- 19 Some of the biologics drugs in different phases of development
- 20 Percentage of population aged 60 years or above
- 21 Percentages of population aged 60 or over.
- 22 Overview: AbbVie Inc.
- 23 Overview: Albany Molecular Research Inc.
- 24 Overview: Allergan plc.
- 25 Overview: Amgen Inc.
- 26 Overview: Aptuit
- 27 Overview: Astellas Pharma Inc.
- 28 Overview: AstraZeneca PLC
- 29 Overview: Bayer AG
- 30 Overview: Biocon Ltd.
- 31 Overview: Boehringer Ingelheim GmbH
- 32 Overview: BRISTOL-MYERS SQUIBB COMPANY
- 33 Overview: Charles River Laboratories International, Inc.
- 34 Overview: Eli Lilly and Company
- 35 Overview: Evotec AG

- 36 Overview: F. Hoffmann-La Roche AG
- 37 Overview: GenScript
- 38 Overview: GILEAD SCIENCES, INC.
- 39 Overview: GlaxoSmithKline Plc
- 40 Overview: JOHNSON & JOHNSON
- 41 Overview: Laboratory Corporation of America Holdings
- 42 Overview: Merck KGaA
- 43 Overview: Merck & CO., Inc.
- 44 Overview: Novartis AG
- 45 Overview: NOVO NORDISK
- 46 Overview: Pfizer Inc.
- 47 Overview: Sanofi
- 48 Overview: Teva Pharmaceuticals Industries Limited
- 49 Overview: WuXi Apptec

List Of Figures

LIST OF FIGURES

- 1 Global Biologics Drug Discovery Market Value, 2015-2025 (\$Million)
- 2 Global Drug Discovery Market Value, 2015-2025 (\$Million)
- 3 Global Biologics Drug Discovery Market, 2016-2025 (\$Million), by phase
- 4 Global Biologic Drug Discovery Market by Manufacture Type, 2016
- 5 Global Biologic Drug Discovery Market by Manufacture Type, 2025
- 6 Global Biologics Drug Discovery Market, by Product Type, 2016
- 7 Global Biologics Drug Discovery Market, by Product Type, 2025
- 8 Global Biologics Drug Discovery Market Value by Geography, 2016 & 2025 (\$Million)
- 9 Global Biologics Drug Discovery Market, by Geography, 2016
- 10 Global Biologics Drug Discovery Market, by Geography, 2025
- 11 Global Biologics Drug Discovery Market Segmentation
- 12 Research Methodology
- 13 Data Triangulation
- 14 Key Data Points From Secondary Sources
- 15 Key Data Points From Primary Sources
- 16 Top-Down Approach (Segmental Analysis)
- 17 Bottom-Up Approach (Segmental Analysis)
- 18 Assumptions and Limitations
- 19 Drug Discovery of Biologics
- 20 Share of Key Development & Strategies
- 21 Porter's Five Forces Analysis
- 22 Drug Market by product type, 2016-2023 (in \$Million)
- 23 Hybridoma technique of monoclonal antibody production
- 24 Methods of Humanization of Antibodies
- 25 Monoclonal Antibody Drug Discovery Market by product type, 2016-2025 (in \$million)
- 26 Global monoclonal antibody target identification market, 2016-2025 (in \$million)
- 27 Global monoclonal antibody hit generation/validation market, 2016-2025 (in \$million)
- 28 Global monoclonal antibody lead identification market, 2016-2025 (in \$million)
- 29 Global monoclonal antibody lead optimization market, 2016-2025 (in \$million)
- 30 Factors affecting choice of cells
- 31 Recombinant Proteins Drug Discovery Market by method type, 2016-2025 (in \$Million)
- 32 Global recombinant protein target identification market, 2016-2025 (in \$million)
- 33 Global recombinant protein hit generation/validation market, 2016-2025 (in \$million)
- 34 Global recombinant protein lead identification market, 2016-2025 (in \$million)

- 35 Global recombinant protein lead optimization market, 2016-2025 (in \$million)
- 36 Global Biologics Drug Discovery Market, by phase, 2016-2025 (in \$million)
- 37 Characteristics of a Disease Model
- 38 Global Biologics Drug Discovery Market, by phase, 2016-2025 (in \$million)
- 39 Methods for Hybridoma Screening
- 40 Global Biologics Drug Discovery Market, Hit Generation, 2016-2025 (in \$million)
- 41 Global Biologics Drug Discovery Market, Lead Identification, 2016-2025 (in \$million)
- 42 Methods for humanization of antibodies
- 43 Global Biologics Drug Discovery Market, Lead Optimization, 2016-2025 (in \$million)
- 44 Examples of Some of The Pharmaceutical Companies
- 45 Examples of Some of The Contract Research Organisations
- 46 Drug Market by manufacture type, 2016-2023 (in \$million)
- 47 Global Biologics Drug Discovery Market, By Geography
- 48 Global Biologics Drug Discovery Market, 2016-2025, by geography (in \$Million)
- 49 Global Biologics Drug Discovery Market, 2016-2025, North America (in \$Million)
- 50 Global Biologics Drug Discovery Market, 2016-2025, North America, by Manufacture Type (in \$Million)
- 51 The U.S. Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 52 Canada Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 53 Global Biologics Drug Discovery Market, 2016-2025, Europe (in \$Million)
- 54 Global Biologics Drug Discovery Market, 2016-2025, Europe, by Manufacture Type (in \$Million)
- 55 Germany Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 56 The U.K. Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 57 France Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 58 Switzerland Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 59 Rest of Europe Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 60 Global Biologics Drug Discovery Market, 2016-2025, Asia Pacific (in \$Million)
- 61 Global Biologics Drug Discovery Market, 2016-2025, Asia Pacific, by Manufacture Type (in \$Million)
- 62 Japan Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 63 China Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 64 India Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 65 Australia Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 66 Rest of Asia Pacific Biologics Drug Discovery Market Value, 2016-2025 (\$Million)
- 67 AbbVie Inc.: Product Portfolio
- 68 AbbVie Inc.: Overall Financials (2014-2016)
- 69 AbbVie Inc.: Net Sales by Geographic Destination (2014-2016)
- 70 AbbVie Inc.: SWOT Analysis

- 71 Albany Molecular Research Inc.: Product/ Services Portfolio
- 72 Albany Molecular Research Inc.: Overall Financials
- 73 Albany Molecular Research Inc.: Net revenue by company segment
- 74 Albany Molecular Research Inc.: Contract Revenue by Geography
- 75 Albany Molecular Research Inc: SWOT Analysis
- 76 Allergan plc.: Product Portfolio
- 77 Allergan plc: Overall Financials (2014-2016)
- 78 Allergan plc: Net Sales by Business Segments (2015-2016)
- 79 Allergan plc: Net Sales by Business Segment (2014)
- 80 Allergan plc: SWOT Analysis
- 81 Amgen Inc.: Product Portfolio
- 82 Amgen Inc.: Overall Financials (2014-2016)
- 83 Amgen Inc.: Net Sales by Geographic Destination (2014-2016)
- 84 Amgen Inc.: SWOT Analysis
- 85 Aptuit: Product/Services Portfolio
- 86 Aptuit: SWOT Analysis
- 87 Astellas Pharma Inc.: Product Portfolio
- 88 Astellas Pharma Inc.: Overall Financials (2014-2016)
- 89 Astellas Pharma Inc.: Net Sales by Product Type (2014-2016)
- 90 Astellas Pharma Inc.: Net Sales by Geographic Destination (2014-2016)
- 91 Astellas Pharma Inc.: SWOT Analysis
- 92 AstraZeneca PLC: Product Portfolio
- 93 AstraZeneca PLC: Overall Financials, 2014-2016
- 94 AstraZeneca PLC: Net Revenue by Business Segment, 2014-2016
- 95 AstraZeneca PLC: Revenue across Different Geographies, 2014-2016
- 96 AstraZeneca PLC: SWOT Analysis
- 97 Bayer AG: Product Portfolio
- 98 Bayer AG: Overall Financials, 2014-2016
- 99 Bayer AG: Net Revenue by Business Segment, 2014-2016
- 100 Bayer AG: Net Revenue by Geographic Destination, 2014-2016
- 101 Bayer AG: SWOT Analysis
- 102 Biocon Ltd.: Product Portfolio
- 103 Biocon Ltd.: Overall Financials, 2015-2017
- 104 Biocon Ltd.: Net Revenue by Business Segment, 2015-2017
- 105 Biocon Ltd.: Net Revenue by Pharma Business Segment, 2014-2016
- 106 Biocon Ltd.: Revenue across Different Geographies, 2014-2016
- 107 Biocon Ltd.: SWOT Analysis
- 108 Boehringer Ingelheim GmbH: Product Portfolio
- 109 Boehringer Ingelheim GmbH: Overall Financials (2014-2016)

- 110 Boehringer Ingelheim GmbH: Net Sales by Product Type (2014-2016)
- 111 Boehringer Ingelheim GmbH: Net Sales by Geographic Destination (2014-2016)
- 112 Boehringer Ingelheim GmbH: SWOT Analysis
- 113 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio
- 114 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016)
- 115 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016)
- 116 BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016)
- 117 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
- 118 Charles River Laboratories: Product/Services Portfolio
- 119 Charles River Laboratories: Overall Financials
- 120 Charles River Laboratories: Net sales by product segment
- 121 Charles River Laboratories: Net sales by Geography
- 122 Charles River Laboratories: SWOT Analysis
- 123 Eli Lilly and Company: Product Portfolio
- 124 Eli Lilly and Company: Overall Financials (2014-2016)
- 125 Eli Lilly and Company: Net Sales by Product Type (2014-2016)
- 126 Eli Lilly and Company: Net Sales by Geographic Destination (2014-2016)
- 127 Eli Lilly and Company: SWOT Analysis
- 128 Evotec AG: Product/Services Portfolio
- 129 Evotec AG: Overall Financials (2014-2016)
- 130 Evotec AG: Net Revenue by Business Segment
- 131 Evotec AG: Net Revenue by Region (2014-2016)
- 132 Evotec: SWOT Analysis
- 133 Roche AG: Product Portfolio
- 134 Roche AG: Overall Financials, (2013–2016)
- 135 Roche AG: Revenue across Different Geographies,
- 136 Roche AG: Net Revenue by Business Segment, (2013-2016)
- 137 Roche AG: SWOT Analysis
- 138 GenScript: Product/Services Portfolio
- 139 GenScript: SWOT Analysis
- 140 GILEAD SCIENCES, INC.: Product Portfolio
- 141 GILEAD SCIENCES, INC.: Overall Financials (2014-2016)
- 142 GILEAD SCIENCES, INC.: Net Sales by Geographic Destination (2014-2016)
- 143 GILEAD SCIENCES, INC.: SWOT Analysis
- 144 GSK: Product Portfolio
- 145 GSK: Overall Financials (2013-2016)
- 146 GSK: Net Revenue by Business Segments (2013-2016)
- 147 GSK: Net Revenue by Geography (2013-2015)

- 148 GSK: Net Revenue by Geography (2016)
- 149 GlaxoSmithKline Plc: SWOT Analysis
- 150 JOHNSON & JOHNSON: Product Portfolio
- 151 JOHNSON & JOHNSON: Overall Financials (2014-2016)
- 152 JOHNSON & JOHNSON: Net Revenue by Business Segment
- 153 JOHNSON & JOHNSON: Net Revenue by Region (2014-2016)
- 154 JOHNSON & JOHNSON: SWOT Analysis
- 155 Laboratory Corporation of America Holdings: Product/Services Portfolio
- 156 Laboratory Corporation of America Holdings: Overall Financials
- 157 Laboratory Corporation of America Holdings: Net sales by services segment
- 158 Laboratory Corporation of America Holdings: Net sales by Geography
- 159 Laboratory Corporation of America Holdings: SWOT Analysis
- 160 Merck & CO., Inc. KGaA: Overall Financials, (2014-2016)
- 161 Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016)
- 162 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014)
- 163 Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016)
- 164 Merck KGaA: SWOT Analysis
- 165 Merck & CO., Inc.: Product Portfolio
- 166 Merck & CO., Inc.: Overall Financials (2013-2016)
- 167 Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014)
- 168 Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016)
- 169 Merck & CO., Inc.: Net Revenue by Geography (2013-2014)
- 170 Merck & CO., Inc.: Net Revenue by Geography (2015-2016)
- 171 Merck & Co., Inc.: SWOT Analysis
- 172 Novartis: Product Portfolio
- 173 Novartis: Overall Financials (2013-2016)
- 174 Novartis: Net Revenue by Geography
- 175 Novartis: Net Revenue by Business Segments
- 176 Novartis: Net Revenue by Business Segments (2015-2016)
- 177 Novartis AG: SWOT Analysis
- 178 Novo Nordisk: Product Portfolio
- 179 Novo Nordisk: Overall Financials, 2014-2016
- 180 Novo Nordisk: Net Revenue by Business Segment, 2014-2016
- 181 Novo Nordisk: Revenue across Different Geographies, 2014-2016
- 182 NOVO Nordisk: SWOT Analysis
- 183 Pfizer: Product Portfolio
- 184 Pfizer: Overall Financials (2013-2016)
- 185 Pfizer: Net Revenue by Geography (2013-2016)
- 186 Pfizer: Net Revenue by Business Segments (2013-2014)

- 187 Pfizer: Net Revenue by Business Segments (2015-2016)
- 188 Pfizer Inc.: SWOT Analysis
- 189 Sanofi: Product Portfolio
- 190 Sanofi: Overall Financials (2014-2016)
- 191 Sanofi: Net Sales by Business Segments (2014-2016)
- 192 Sanofi: Net Sales by Geographic Destination (2014-2016)
- 193 Sanofi: Net Sales by Franchise (2014-2016)
- 194 Sanofi: SWOT Analysis
- 195 Teva Pharmaceutical Industries Limited: Product Portfolio
- 196 Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016)
- 197 Teva Pharmaceutical Industries Limited: Net Revenue by Business Segments, (2013-2016)
- 198 Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016)
- 199 Teva Pharmaceutical Industries Ltd.: SWOT Analysis
- 200 WuXi Apptec: Product/Services Portfolio
- 201 WuXi Apptec: SWOT Analysis

I would like to order

Product name: Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025) (Focus on Method/Phase, Product Type, Manufacturer Type and Competitive Landscape)

Product link: <https://marketpublishers.com/r/GE987C530F8EEN.html>

Price: US\$ 4,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE987C530F8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

